Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

39.16 +0.18 (+0.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,371,259
Open 39.69
Bid (Size) 38.70 (200)
Ask (Size) 40.05 (200)
Prev. Close 38.98
Today's Range 38.53 - 40.08
52wk Range 3.720 - 41.27
Shares Outstanding 85,465,249
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+402.1%
+402.1%
1 Month
+152.6%
+152.6%
3 Month
+199.4%
+199.4%
6 Month
+594.3%
+594.3%
1 Year
+326.1%
+326.1%

More News

Read More
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
Via The Motley Fool
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Gold Jumps Over 2%; Dole Shares Gain After Q3 Results ↗
Via Benzinga
News headline image
Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise ↗
Via Investor's Business Daily
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial ↗
Via Benzinga
News headline image
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
S&P 500 Surges 1%; Tyson Foods Posts Upbeat Earnings ↗
Via Benzinga
Topics Stocks
News headline image
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results
Via MarketMinute
Topics Economy Supply Chain
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags ↗
Via Benzinga
News headline image
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges ↗
Via Stocktwits
News headline image
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst ↗
Via Benzinga
News headline image
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗
Via Benzinga
Topics Artificial Intelligence Government
News headline image
Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear & Greed Index Remains In 'Extreme Greed' Zone ↗
Via Benzinga
Topics Government Stocks

Frequently Asked Questions

Is Cogent Biosciences, Inc. - Common Stock publicly traded?
Yes, Cogent Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cogent Biosciences, Inc. - Common Stock trade on?
Cogent Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cogent Biosciences, Inc. - Common Stock?
The ticker symbol for Cogent Biosciences, Inc. - Common Stock is COGT on the Nasdaq Stock Market
What is the current price of Cogent Biosciences, Inc. - Common Stock?
The current price of Cogent Biosciences, Inc. - Common Stock is 39.16
When was Cogent Biosciences, Inc. - Common Stock last traded?
The last trade of Cogent Biosciences, Inc. - Common Stock was at 12/03/25 04:00 PM ET
What is the market capitalization of Cogent Biosciences, Inc. - Common Stock?
The market capitalization of Cogent Biosciences, Inc. - Common Stock is 3.35B
How many shares of Cogent Biosciences, Inc. - Common Stock are outstanding?
Cogent Biosciences, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.